Last reviewed · How we verify
Cetirizine and Famotidine
At a glance
| Generic name | Cetirizine and Famotidine |
|---|---|
| Also known as | Zyrtec, Pepcid |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (PHASE1)
- Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial (PHASE3)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
- Cetirizine and Famotidine for COVID-19 (PHASE4)
- Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetirizine and Famotidine CI brief — competitive landscape report
- Cetirizine and Famotidine updates RSS · CI watch RSS
- Emory University portfolio CI